J. C. Brelière

1.9k total citations · 1 hit paper
27 papers, 1.6k citations indexed

About

J. C. Brelière is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Physiology. According to data from OpenAlex, J. C. Brelière has authored 27 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Cellular and Molecular Neuroscience, 18 papers in Molecular Biology and 4 papers in Physiology. Recurrent topics in J. C. Brelière's work include Receptor Mechanisms and Signaling (16 papers), Neuropeptides and Animal Physiology (15 papers) and Pharmacological Receptor Mechanisms and Effects (4 papers). J. C. Brelière is often cited by papers focused on Receptor Mechanisms and Signaling (16 papers), Neuropeptides and Animal Physiology (15 papers) and Pharmacological Receptor Mechanisms and Effects (4 papers). J. C. Brelière collaborates with scholars based in France, Denmark and Italy. J. C. Brelière's co-authors include Xavier Emonds‐Alt, G. Néliat, G. Le Fur, Charles Advenier, Emmanuel Naline, M Rinaldi-Carmona, Christian Congy, P. Vilain, Didier Van Broeck and Pierre Casellas and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Biochemical and Biophysical Research Communications and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

J. C. Brelière

26 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor

1998 593 citations M Rinaldi-Carmona, Francis Barth et al. Journal of Pharmacology and Experimental Therapeutics profile →

Peers

J. C. Brelière

CMN

PHARM

PHYSI

EAS

Florence Oury-Donat France

Jean-Claude Brelière France

M. Conrath France

Vincent Santucci France

Anne‐Marie Galzin France

Sigismund Huck Austria

Timothy M. Piser United States

Areles Molleman United Kingdom

Anne Rémaury France

Paul J. Emmerson United States

Florence Oury-Donat France

J. C. Brelière

973 ×0.9

CMN

841 ×1.0

835 ×1.4

PHARM

426 ×1.5

PHYSI

211 ×1.4

EAS

Citations per year, relative to J. C. Brelière J. C. Brelière (= 1×) peers Florence Oury-Donat

Countries citing papers authored by J. C. Brelière

Since Specialization

Citations

This map shows the geographic impact of J. C. Brelière's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. C. Brelière with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. C. Brelière more than expected).

Fields of papers citing papers by J. C. Brelière

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. C. Brelière. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. C. Brelière. The network helps show where J. C. Brelière may publish in the future.

Co-authorship network of co-authors of J. C. Brelière

This figure shows the co-authorship network connecting the top 25 collaborators of J. C. Brelière. A scholar is included among the top collaborators of J. C. Brelière based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. C. Brelière. J. C. Brelière is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Alonso, Richard, et al.. (1998). Effects of SR140333, a selective non‐peptide NK₁ receptor antagonist, on trigemino‐thalamic nociceptive pathways in the rat. Fundamental and Clinical Pharmacology. 12(1). 88–94. 10 indexed citations

Rinaldi-Carmona, M, Francis Barth, Jean‐Marie Derocq, et al.. (1998). SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor. Journal of Pharmacology and Experimental Therapeutics. 284(2). 644–650. 593 indexed citations breakdown →

Emonds‐Alt, Xavier, Charles Advenier, Tiziano Croci, et al.. (1997). Biochemical and pharmacological activities of SR 144190, a new potent non-peptide tachykinin NK2 receptor antagonist. Neuropeptides. 31(5). 449–458. 32 indexed citations

Gether, Ulrik, Xavier Emonds‐Alt, J. C. Brelière, et al.. (1994). Evidence for a common molecular mode of action for chemically distinct nonpeptide antagonists at the neurokinin-1 (substance P) receptor.. Molecular Pharmacology. 45(3). 500–508. 24 indexed citations

Jung, M., Jeanne Maruani, J. Souilhac, et al.. (1994). Neuropharmacological characterization of SR 140333, a non peptide antagonist of NK1 receptors. Neuropharmacology. 33(2). 167–179. 52 indexed citations

Gougat, Jean, C Lacour, Alain Roccon, et al.. (1994). Cyclopentanespiro-3H-dihydro-pyrimidinones as Angiotensin II AT1 receptor antagonists. Bioorganic & Medicinal Chemistry Letters. 4(1). 157–162. 5 indexed citations

Ferrari, Bernard, Jacques Clément, Jean Gougat, et al.. (1994). ChemInform Abstract: A New Series of Imidazolones: Highly Specific and Potent Nonpeptide AT1 Angiotensin II Receptor Antagonists.. ChemInform. 25(11).

Emonds‐Alt, Xavier, et al.. (1994). Characterization of the binding sites of [3H]SR140333, a potent non-peptide radioligand antagonist of the tachykinin NK1 receptor. Neuropeptides. 26. 38–38. 3 indexed citations

Rinaldi-Carmona, M, Christian Congy, Jacques Simiand, et al.. (1993). Repeated administration of SR 46349B, a selective 5-hydroxytryptamine2 antagonist, up-regulates 5-hydroxytryptamine2 receptors in mouse brain.. Molecular Pharmacology. 43(1). 84–89. 27 indexed citations

10.

Emonds‐Alt, Xavier, et al.. (1993). Characterization of the Binding Sites of [3H]SR 48968, a Potent Nonpeptide Radioligand Antagonist of the Neurokinin-2 Receptor. Biochemical and Biophysical Research Communications. 191(3). 1172–1177. 31 indexed citations

11.

Poncelet, Martine, Vincent Santucci, Raymond Paul, et al.. (1993). Neuropharmacological profile of a novel and selective ligand of the sigma site: SR 31742A. Neuropharmacology. 32(6). 605–615. 34 indexed citations

12.

Emonds‐Alt, Xavier, Jean-Daniel Doutremepuich, M. Jung, et al.. (1993). SR 140333, a non-peptide antagonist of substance-P (NK1) receptor. Neuropeptides. 24(4). 231–231. 12 indexed citations

13.

Gether, Ulrik, Yoshifumi Yokota, Xavier Emonds‐Alt, et al.. (1993). Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors.. Proceedings of the National Academy of Sciences. 90(13). 6194–6198. 59 indexed citations

14.

Emonds‐Alt, Xavier, P. Vilain, Vincenzo Proietto, et al.. (1992). A potent and selective non-peptide antagonist of the neurokinin a (NK2) receptor. Life Sciences. 50(15). PL101–PL106. 397 indexed citations

15.

Rinaldi-Carmona, M, Christian Congy, Vincent Santucci, et al.. (1992). Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist.. Journal of Pharmacology and Experimental Therapeutics. 262(2). 759–768. 100 indexed citations

16.

Emonds‐Alt, Xavier, Charles Advenier, P. Vilain, et al.. (1992). Pharmacological profile of SR 48968, a potent non-peptide antagonist of the neurokinin A (NK2) receptor. Neuropeptides. 22(1). 21–22. 9 indexed citations

17.

Barbier, A., et al.. (1986). Studies on the chronic phase of adjuvant arthritis: effect of SR 41319, a new diphosphonate.. Annals of the Rheumatic Diseases. 45(1). 67–74. 38 indexed citations

18.

Barbier, A., et al.. (1986). Effect of (chloro-4-phenyl) thiomethylene bisphosphonic acid (SR 41319) on the autoimmune disease activity in MRL/1 mice. Inflammation Research. 19(5-6). 311–312. 1 indexed citations

19.

Barbier, A., J. C. Brelière, Raymond Paul, & R. Roncucci. (1985). Comparative study of etidronate and SR 41319, a new diphosphonate, on passive cutaneous anaphylaxis and phospholipase A2 activity. Inflammation Research. 16(1-2). 41–42. 5 indexed citations

20.

Barbier, A., et al.. (1984). Biochemical and clinical changes in rats with developing adjuvant arthritis. Inflammation Research. 15(1-2). 103–105. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact